Related references
Note: Only part of the references are listed.Chemotherapy-induced neuropathy
Anthony J. Windebank et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
The Pharmacologic management of cancer pain
James F. Cleary
JOURNAL OF PALLIATIVE MEDICINE (2007)
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
Guido Cavaletti et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2007)
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Quantitative sensory findings in patients with bortezomib-induced pain
Juan P. Cata et al.
JOURNAL OF PAIN (2007)
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Guido Cavaletti et al.
EXPERIMENTAL NEUROLOGY (2007)
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
Ashraf Badros et al.
CANCER (2007)
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248
Steven P. Treon et al.
CLINICAL CANCER RESEARCH (2007)
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
Linda Mileshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A Multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma
Soo-Mee Bang et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
AA Argyriou et al.
SUPPORTIVE CARE IN CANCER (2006)
A practical update on the use of bortezomib in the management of multiple myeloma
Jesus San Miguel et al.
ONCOLOGIST (2006)
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
G Jackson et al.
CANCER TREATMENT REVIEWS (2005)
Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?
AA Argyriou et al.
SUPPORTIVE CARE IN CANCER (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/Bortezomib) cytotoxicity in myeloma cell lines
TH Landowski et al.
CANCER RESEARCH (2005)
Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
S Jagannath et al.
CANCER (2005)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
Pyridoxine (Vitamin B6) neurotoxicity: Enhancement by protein-deficient diet
S Levine et al.
JOURNAL OF APPLIED TOXICOLOGY (2004)
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale
G Cavaletti et al.
NEUROLOGY (2003)
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy
EA Calhoun et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases
C Zarow et al.
ARCHIVES OF NEUROLOGY (2003)
Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats
S Levine et al.
FOOD AND CHEMICAL TOXICOLOGY (2002)
Cytoplasmic changes in satellite cells of spinal ganglia induced by cisplatin treatment in rats
G Corsetti et al.
ULTRASTRUCTURAL PATHOLOGY (2000)
Share Paper
